As Congress and the Trump Administration consider policies to address rising prescription drug prices, the National Coalition on Health Care (NCHC) hosted a Capitol Hill briefing on March 15th to put one promising option on the table: the use of binding arbitration in Medicare Part D to determine prices for a limited set of drugs. […]
Juvenile diabetes is an autoimmune disorder that affects over 1.25 million Americans. Also known as Type 1 diabetes, it occurs when the body stops producing the blood-glucose regulating hormone insulin; thus, juvenile diabetics must receive consistent insulin therapy to survive. Although insulin was discovered in the 1920s, prices for the drug are astronomical by today’s […]
By: John Rother The problem of unaffordable prescription drug prices is not a simple on, nor is there a single policy that addresses the full range of issues. We need to fix the current broken system to make drugs more affordable while maintaining incentives to discover important new cures. There are seven “deadly sins” that now characterize […]
By John RotherBlog post from January 7, 2018 There were two big stories from the pharmaceutical industry this week, both reported by the Wall Street Journal: 1) Bristol-Myers Squibb intends to acquire Celgene in a $74 billion dollar deal; and 2) drug manufacturers have already hiked prices for hundreds of medicines for 2019. Both stories […]
With 2018 now underway, the National Coalition on Health Care has been reflecting on the tumult of the past year and what we have learned. There has been so much going on in health care and health policy, much of it negative, that it’s difficult to form a simple assessment of the possible impact going forward. Here are ten significant observations as I reflect back on 2017.